Cargando…
Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview
Endocrine therapy-induced hair loss (ETIHL) associated with aromatase inhibitors and tamoxifen treatment is currently mostly reported but remained an unresolved therapeutic issue in patients with breast cancer (BC) since the number of studies regarding the management is limited in literature. Herein...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864803/ https://www.ncbi.nlm.nih.gov/pubmed/27247882 http://dx.doi.org/10.1186/s40064-016-2216-3 |
_version_ | 1782431679455952896 |
---|---|
author | Karatas, Fatih Sahin, Suleyman Sever, Ali R. Altundag, Kadri |
author_facet | Karatas, Fatih Sahin, Suleyman Sever, Ali R. Altundag, Kadri |
author_sort | Karatas, Fatih |
collection | PubMed |
description | Endocrine therapy-induced hair loss (ETIHL) associated with aromatase inhibitors and tamoxifen treatment is currently mostly reported but remained an unresolved therapeutic issue in patients with breast cancer (BC) since the number of studies regarding the management is limited in literature. Herein we investigated the possible causes of this clinical problem and its relation with endocrine therapies widely used for BC survivors and made some modest practical recommendations in light of the literature review in order to provide an optimal management. On the basis of literature findings, common causes of hair loss apart from endocrine therapies should be investigated with an initial evaluation workup and then should be corrected, if observed. Treatment with topical 5-alpha reductase inhibitors and supplementation of Vitamin C and omega-3 fatty acids are likely appeared to be the most appropriate treatment agents for ETIHL without causing an adverse effect on BC prognosis. However, more prospective, randomised, placebo-controlled studied are required in order to confirm our results and also identify the clinical effects of this problem on patients with BC. |
format | Online Article Text |
id | pubmed-4864803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-48648032016-05-31 Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview Karatas, Fatih Sahin, Suleyman Sever, Ali R. Altundag, Kadri Springerplus Review Endocrine therapy-induced hair loss (ETIHL) associated with aromatase inhibitors and tamoxifen treatment is currently mostly reported but remained an unresolved therapeutic issue in patients with breast cancer (BC) since the number of studies regarding the management is limited in literature. Herein we investigated the possible causes of this clinical problem and its relation with endocrine therapies widely used for BC survivors and made some modest practical recommendations in light of the literature review in order to provide an optimal management. On the basis of literature findings, common causes of hair loss apart from endocrine therapies should be investigated with an initial evaluation workup and then should be corrected, if observed. Treatment with topical 5-alpha reductase inhibitors and supplementation of Vitamin C and omega-3 fatty acids are likely appeared to be the most appropriate treatment agents for ETIHL without causing an adverse effect on BC prognosis. However, more prospective, randomised, placebo-controlled studied are required in order to confirm our results and also identify the clinical effects of this problem on patients with BC. Springer International Publishing 2016-05-10 /pmc/articles/PMC4864803/ /pubmed/27247882 http://dx.doi.org/10.1186/s40064-016-2216-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Karatas, Fatih Sahin, Suleyman Sever, Ali R. Altundag, Kadri Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview |
title | Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview |
title_full | Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview |
title_fullStr | Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview |
title_full_unstemmed | Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview |
title_short | Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview |
title_sort | management of hair loss associated with endocrine therapy in patients with breast cancer: an overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864803/ https://www.ncbi.nlm.nih.gov/pubmed/27247882 http://dx.doi.org/10.1186/s40064-016-2216-3 |
work_keys_str_mv | AT karatasfatih managementofhairlossassociatedwithendocrinetherapyinpatientswithbreastcanceranoverview AT sahinsuleyman managementofhairlossassociatedwithendocrinetherapyinpatientswithbreastcanceranoverview AT severalir managementofhairlossassociatedwithendocrinetherapyinpatientswithbreastcanceranoverview AT altundagkadri managementofhairlossassociatedwithendocrinetherapyinpatientswithbreastcanceranoverview |